In short
Rebisufligene Etisparvovec, also known as ABO-102 or UX111, is an innovative gene therapy being studied in clinical trials for the treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA). This rare genetic disorder affects children and is characterized by progressive neurological deterioration. The clinical trials aim to evaluate the safety and effectiveness of this gene therapy, which is administered as a single intravenous injection to potentially restore the metabolic pathway damaged in MPS IIIA patients.
At a glance
- Drug Name
- Rebisufligene Etisparvovec (ABO-102, UX111)
- Condition Treated
- Mucopolysaccharidosis Type IIIA (MPS IIIA)
- Administration Method
- Single intravenous injection
- Trial Phase
- Phase I/II/III Integrated Clinical Trial
- Primary Objectives
- Evaluate safety and efficacy
- Key Efficacy Measures
- CSF heparan sulfate levels, cognitive function scores
- Safety Monitoring
- Incidence of adverse events and serious adverse events
- Participant Age Range
- From birth/3 months to 5 years (varies by cohort)
- Long-term Follow-up
- Separate study to monitor long-term safety and efficacy
What is REBISUFLIGENE ETISPARVOVEC?
REBISUFLIGENE ETISPARVOVEC, also known as ABO-102, scAAV9.U1a.hSGSH, or UX111, is a promising gene therapy medication designed to treat Mucopolysaccharidosis Type IIIA (MPS IIIA). It is a suspension for injection that contains a specially engineered gene therapy vector. This innovative treatment aims to address the underlying genetic cause of MPS IIIA, offering hope to patients and families affected by this rare genetic disorder.
Target Condition: Mucopolysaccharidosis Type IIIA
Mucopolysaccharidosis Type IIIA, also known as Sanfilippo Syndrome Type A, is a rare genetic disorder that affects the body's ability to break down certain complex sugar molecules. This condition is caused by a deficiency in an enzyme called N-sulfoglucosamine sulfohydrolase (SGSH). As a result, harmful substances accumulate in the body, particularly affecting the brain and nervous system, leading to progressive cognitive decline and various other symptoms.
How REBISUFLIGENE ETISPARVOVEC Works
REBISUFLIGENE ETISPARVOVEC is a gene therapy that works by delivering a functional copy of the SGSH gene to cells in the patient's body. The therapy uses a modified virus called AAV9 as a vector to carry the corrective gene. This vector is designed to cross the blood-brain barrier (BBB), allowing it to reach cells in the central nervous system.
Once inside the cells, the therapy enables the production of the missing N-sulfoglucosamine sulfohydrolase enzyme. This helps to restore the metabolic pathway that is damaged in MPS IIIA patients, potentially slowing or halting the progression of the disease.
Clinical Trials and Research
REBISUFLIGENE ETISPARVOVEC is currently being studied in clinical trials to evaluate its safety and effectiveness in treating MPS IIIA. The ongoing research includes:
- A Phase I/II/III integrated clinical trial to assess the drug's efficacy and safety
- Studies involving different age groups, from infants to children up to 5 years old
- Evaluation of various dosages to determine the optimal treatment regimen
Administration and Treatment Process
REBISUFLIGENE ETISPARVOVEC is administered as a single intravenous injection. This means that the medication is given directly into a vein, allowing it to circulate throughout the body. The treatment is designed to be a one-time therapy, potentially providing long-lasting benefits to patients with MPS IIIA.
Safety and Efficacy
The primary goals of the clinical trials for REBISUFLIGENE ETISPARVOVEC are to assess its safety and efficacy. Researchers are monitoring:
- The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
- Changes in cerebrospinal fluid (CSF) heparan sulfate (HS) levels, which is a key indicator of the therapy's effectiveness
- Improvements in cognitive function, as measured by standardized tests like the Bayley Scales of Infant and Toddler Development (BSITD-III)
- Changes in brain structure, such as total cortical volume
Eligibility for Treatment
Eligibility for participation in the clinical trials for REBISUFLIGENE ETISPARVOVEC includes:
- Confirmed diagnosis of MPS IIIA through genetic testing and enzyme activity analysis
- Specific age requirements, ranging from infants to children up to 5 years old, depending on the study cohort
- No prior gene therapy, cell therapy, or enzyme replacement therapy for MPS IIIA
- Absence of certain medical conditions that could interfere with the treatment or study procedures
Long-Term Follow-Up Study
To further evaluate the long-term safety and effectiveness of REBISUFLIGENE ETISPARVOVEC, a separate long-term follow-up study is being conducted. This study aims to:
- Monitor the long-term safety and tolerability of the treatment
- Assess the durability of the treatment's effects on cognitive function and disease progression
- Gather additional data on the therapy's impact on quality of life for patients with MPS IIIA
REBISUFLIGENE ETISPARVOVEC represents a significant advancement in the treatment of Mucopolysaccharidosis Type IIIA. As research continues, this innovative gene therapy offers hope for improved outcomes and quality of life for individuals affected by this rare genetic disorder.